Definium Therapeutics (DFTX) Total Non-Current Liabilities (2020 - 2026)
Definium Therapeutics (DFTX) reported Total Non-Current Liabilities of $121.9 million for Q1 2026, up 13.62% on a QoQ basis from $107.3 million in Q4 2025.
Definium Therapeutics (DFTX) has 7 years of Total Non-Current Liabilities data on file, last reported at $121.9 million in Q1 2026.
- Quarterly Total Non-Current Liabilities changed N/A year-over-year to $121.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $121.9 million (changed N/A YoY) and the FY2025 annual result came in at $107.3 million, changed N/A from the prior year.
- Total Non-Current Liabilities advanced to $121.9 million in Q1 2026 per DFTX's latest filing, from $107.3 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $121.9 million in Q1 2026 and bottomed at $7.9 million in Q2 2022.
- The 5-year median for Total Non-Current Liabilities is $45.8 million (2023), against an average of $58.0 million.
- Peak annual rise in Total Non-Current Liabilities reached 405.47% in 2022, while the deepest fall reached 71.91% in 2022.
- Tracing DFTX's Total Non-Current Liabilities over 5 years: stood at $17.9 million in 2022, then jumped by 159.19% to $46.4 million in 2023, then soared by 71.34% to $79.5 million in 2024, then surged by 35.01% to $107.3 million in 2025, then grew by 13.62% to $121.9 million in 2026.
- Per Business Quant, the three latest DFTX Total Non-Current Liabilities figures stand at $121.9 million (Q1 2026), $107.3 million (Q4 2025), and $105.8 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 7.32 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Definium Therapeutics | 2.42 Bn | 2.06 Bn | - | 121.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 121.89 Mn |
| Dec 31, 2025 | 107.28 Mn |
| Sep 30, 2025 | 105.80 Mn |
| Jun 30, 2025 | 79.15 Mn |
| Mar 31, 2024 | 79.46 Mn |
| Dec 31, 2023 | 46.38 Mn |
| Sep 30, 2023 | 45.22 Mn |
| Jun 30, 2023 | 35.12 Mn |
| Mar 31, 2023 | 24.10 Mn |
| Dec 31, 2022 | 17.89 Mn |
| Sep 30, 2022 | 26.04 Mn |
| Jun 30, 2022 | 7.87 Mn |
| Dec 31, 2021 | 10.41 Mn |
| Sep 30, 2021 | -8.52 Mn |
| Jun 30, 2021 | -3.70 Mn |
| Dec 31, 2020 | 5.65 Mn |
| Mar 31, 2020 | -9.68 Mn |